

# Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in biomarkers of liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: A randomized, blinded, placebo-controlled Phase 2A trial

<u>ROHIT LOOMBA<sup>1</sup>, KRIS KOWDLEY<sup>2</sup>, JOSE RODRIGUEZ<sup>3</sup>, NOMITA J. KIM<sup>4</sup>, ALINA MARAVADI<sup>7,†</sup>, BRENDA JEGLINSKI<sup>7</sup>, ALICIA CLAWSON<sup>7</sup>, SWAPAN CHOWDHURY<sup>7</sup>, CRAIG BASSON<sup>7,‡</sup>, ETIENNE DUMONT<sup>7</sup>, ERIC SVENSSON<sup>7</sup>, TATJANA ODRLJIN<sup>7</sup></u> <sup>1</sup>NAFLD Research Center University of California at San Diego, La Jolla, USA. <sup>2</sup>Liver Institute Northwest, Seattle, USA. <sup>3</sup>Southwest General Healthcare Center, Fort Myers, USA. <sup>4</sup>Accelemed Research, Austin, USA. <sup>6</sup>Prosciento. Inc, Chula Vista, USA. <sup>7</sup>Boston Pharmaceuticals, Cambridge, USA. Current affiliations: \*Pemi River Health LLC, Boston, USA. \*Consultant, Boston, USA. \*Bitterroot Bio, Palo Alto, USA.

## INTRODUCTION

Fibroblast growth factor 21 (FGF21) regulates energy balance and glucose and lipid homeostasis through a heterodimeric receptor complex comprising specific FGF rec and  $\beta$ -Klotho.<sup>1</sup>

BOS-580 is an investigational, genetically engineered analog of human FGF21 fused N-terminus to the Fc fragment of human immunoglobulin G1 (IgG1), stabilized via t introduction of novel disulfide bonds, and uniquely manufactured from a CHO cell generating proper glycosylation, resulting in an extended half-life that allows for on monthly dosing.<sup>2</sup>

BOS-580 has previously been shown in clinical trials to significantly reduce hepatic well as improve biomarkers of glucose and lipid metabolism in obese, mildly hypertriglyceridemic patients after receiving 3 monthly doses of 300mg. Gastrointestinal AEs were mild to moderate and rarely led to discontinuations.<sup>2</sup>

### **DEMOGRAPHICS AND BASELINE CHARACTERISTICS**

Parameter	Placebo (N=37)	75mg Q4W (N=8)	75mg Q2W (N=14)	150mg Q4W (N=15)	150mg Q2W (N=15)	300mg Q4W (N=13)
Age Mean (years)	54.1	53.5	54.7	52.1	50.7	51.8
Sex (female), n(%)	38	25	71	40	47	46
BMI, kg/m²: Mean	36.5	36.5	38.3	36.2	36.4	34.9
HFF, %: Mean	18.7	24	22	21	21	24
Liver stiffness by VCTE (Fibroscan) (kPa): Mean	8.1	8.4	8.2	8.4	8.4	8.1
AST, IU/L: Mean	29.5	43.1	38.4	29.1	35.0	33.2
Type 2 Diabetes, n (%)	43	25	57	40	47	46
HbA1c, %: Mean	6.26	5.95	6.75	6.05	6.06	6.37
Trigly., mmol/L: Mean	2.20	2.05	1.93	1.77	1.91	2.36
Pro-C3, ng/mL: Mean	13.8	14.5	14.2	12.6	12.9	14.2

**Baseline characteristics were well-balanced across cohorts** 

Note: Summaries based on the Enrolled Analysis Set

### SAFETY

### Low discontinuation rate due to mild to moderate, transient GI events

- Treatment discontinuations due to TEAEs were 2 (5.4%) in placebo and 3 (4.6%) in treated patients
- There were 2 Serious Adverse Events, 1 in placebo and 1 in BOS-580 treated at 150mg Q2W
- No clinically significant findings on ECG, vital signs or trends in safety laboratory parameters
- No worsening of serum low density lipoprotein levels, no cases of adverse events of hypoglycemia and no cases of worsening of pre-existing biliary disease were observed

	Placebo (n=37)	75mg Q4W (n=8)	75mg Q2W (n=14)	150mg Q4W (n=15)	150mg Q2W (n=15)
Any GI AESI Incidence	6 (16%) <sup>a</sup>	1 (13%)	7 (50%)	2 (13%)	6 (40%)
Nausea <sup>b</sup>	3 (8%)	1 (13%)	5 (36%)	2 (13%)	4 (27%)
Vomiting	0	0	3 (21%)	1 (7%)	4 (27%)
Diarrhea	2 (5%)	0	3 (21%)	0	2 (13%)
Increased Appetite <sup>c</sup>	0	0	5 (36%)	2 (13%)	0

### **TEAEs with the highest frequency**


a Includes one patient with gastrointestinal reflux disease not summarized in the preferred term rows.

b Only 1 severe case of nausea in 150mg Q2W c Not considered AESI

A		


ceptors
ceptors d at its the line nce fat as
fat as
estinal

To evaluate the safety, tolerability and dose-response relationship on exploratory endpoints associated with NASH pathology, in patients at high-risk of NASH (phenotypic NASH) with biweekly or once monthly subcutaneous dosing of BOS-580 over 12 weeks, in order to identify the dose levels and regimens for further development.




### NASH BIOMARKERS

### Dose dependent reduction in hepatic fat fraction as measured by MRI-PDFF




### Statistically significant improvement in markers of liver injury




2.06

13.7



Statistically significant reduction of fibrosis biomarker, PRO-C3




# STUDY DESIGN & METHODS (NCT04880031)

# RESULTS

### **Statistically significant responder rates**

### **Percent of Patients Achieving Meaningful Reduction in Hepatic Fat Fraction**



in placebo and up to 42% in treated patients

# CONCLUSION

- BOS-580 resulted in a statistically significant reduction in liver fat content as well as markers of liver injury and fibrosis in phenotypic NASH patients with numerically improved markers of metabolic health, including insulin resistance, with monthly subcutaneous doses  $\geq$  150mg.
- To date, BOS-580 has demonstrated low discontinuation rates in clinical trials. The most commonly observed adverse events have been of GI in nature, which were transient and mild to moderate in severity.
- Further clinical development of BOS-580 for the treatment of NASH is ongoing.



### **Exploratory Objectives**

- Key efficacy biomarkers • Liver fibrosis (VCTE, PRO-C3)
- insulin, C-peptide, HbA1C)
- Within each cohort, patients were randomized 4:1 (BOS 580 vs PBO) with ~15 subjects per cohort
- Patients were assessed for safety and tolerability, pharmacokinetics, and most exploratory efficacy biomarkers every 2 weeks including Week 6 (mid-treatment) and Week 12 (end of treatment)/Week 16 (end of study) Analysis data sets were:
  - Enrolled = 102 (83 completed)
  - Safety = 102
  - Efficacy = 89 (with baseline and week 6 or week 12 MRI-PDFF)
- Statistical significance of difference to placebo at the following levels: \*p<0.05, \*\*p<0.01, \*\*\*p<0.001
- Week 12 results are shown in the figures

(n=12) (n=10) 75mg Q2W (n=12) -0.19 -0.31 -0.35

# with $\geq$ 150mg monthly exposure (not shown)

Statistically significant increase in adiponectin levels of up to 77% (placebo adjusted) was observed in BOS-580 treated patients at all dose levels (not shown)

Based on LSmeans with treatment and baseline value effects in the model on the efficacy analysis set

### **References**:

Placebo

(n=30

- 1. Geng L et al. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol 2020; 16: 654-667.
- 2. Rader DJ et al. LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia. J Clinical Endocrinology 2022; 107(1): e57-570.

Funded by Boston Pharmaceuticals